Alpha-particle emitting atomic generator (actinium-225)-labeled trastuzumab (Herceptin) targeting of breast cancer spheroids: Efficacy versus HER2/neu expression

Clinical Cancer Research

Volumn 10, Issue 13, 2004, Pages 4489-4497

  Ballangrud, Åse M ^a,b   Yang, Wei Hong ^a   Palm, Stig ^a   Enmon, Richard ^a   Borchardt, Paul E ^a   Pellegrini, Virginia A ^a   McDevitt, Michael R ^a   Scheinberg, David A ^a   Sgouros, George ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ACTINIUM; ACTINIUM 225; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; TRASTUZUMAB; TRASTUZUMAB 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID AC 225; UNCLASSIFIED DRUG;

ALPHA RADIATION; ARTICLE; BREAST CANCER; BREAST METASTASIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION BEAM; RADIOIMMUNOTHERAPY; RADIOSENSITIVITY; TUMOR CELL LINE;

ACTINIUM; ALPHA PARTICLES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, RADIATION; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; FLOW CYTOMETRY; HUMANS; MICROSCOPY, CONFOCAL; RADIOIMMUNOTHERAPY; RECEPTOR, ERBB-2; TIME FACTORS;

EID: 3042729733     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0800     Document Type: Article

References (34)

1. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998;58:2825-31.
2. Muss HB, Thor AD, Berry DA, et al. C-Erbb-2 Expression and response to adjuvant therapy in women with node-positive early breast-cancer. N Eng J Med 1994;330:1260-6.
3. Ligibel JA, Winer EP. Trastuzumab/chemotherapy combinations in metastatic breast cancer. Semin Oncol 2002;29:38-43.
4. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
5. Natali PG, Nicotra MR, Bigotti A, et al. Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer 1990;45:457-61.
6. Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, Bernstein L. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 2002;20:3095-105.
7. Niehans GA, Singleton TP, Dykoski D, Kiang DT. Stability of HER-2/neu expression over time and at multiple metastatic sites. J Natl Cancer Inst 1993;85:1230-5.
8. De Santes K, Slamon D, Anderson SK, et al. Radiolabeled antibody targeting of the HER-2/neu oncoprotein. Cancer Res 1992;52:1916-23.
9. Kotts CE, Su FM, Leddy C, et al. 186Re-labeled antibodies to p185HER2 as HER2-targeted radioimmunopharmaceutical agents: comparison of physical and biological characteristics with 125I and 131I-labeled counterparts. Cancer Biother Radiopharm 1996;11:133-44.
10. Palm S, Enmon RM Jr, Matei C, et al. Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y Dosimetry in an Ovarian Carcinoma Model: Correlative MicroPET and MRI. J Nucl Med 2003;44:1148-55.
11. Horak E, Hartmann F, Garmestani K, et al. Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1. J Nucl Med 1997;38:1944-50.
12. Geerlings MW, Kaspersen FM, Apostolidis C, van der Hout R. The feasibility of 225Ac as a source of alpha-particles in radioimmunotherapy. Nucl Med Commun 1993;14:121-5.
13. McDevitt MR, Ma D, Simon J, Frank RK, Scheinberg DA. Design and synthesis of 225Ac radioimmunopharmaceuticals. Appl Radiat Isot 2002;57:841-7.
14. Borchardt PE, Yuan RR, Miederer M, McDevitt MR, Scheinberg DA. Targeted actinium-225 in vivo generators for therapy of ovarian cancer. Cancer Res 2003;63:5084-90.
15. Sgouros G, Ballangrud AM, Jurcic JG, et al. Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med 1999;40:1935-46.
16. Jurcic JG, Larson SM, Sgouros G, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 2002;100:1233-9.
17. Kennel SJ, Chappell LL, Dadachova K, et al. Evaluation of 225Ac for vascular targeted radioimmunotherapy of lung tumors. Cancer Biother Radiopharm 2000;15:235-44.
18. McDevitt MR, Ma D, Lai LT, et al. Tumor therapy with targeted atomic nanogenerators. Science 2001;294:1537-40.
19. Miederer M, McDevitt MR, Sgouros G, Kramer K, Cheung NK, Scheinberg DA. Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates. J Nucl Med 2004;45:129-37.
20. Sutherland RM. Cell and environment interactions in tumor microregions: the multicell spheroid model. Science 1988;240:177-84.
21. Yuhas JM, Li AP, Martinez AO, Ladman AJ. A simplified method for production and growth of multicellular tumor spheroids. Cancer Res 1977;37:3639-43.
22. Ballangrud AM, Yang WH, Dnistrian A, Lampen NM, Sgouros G. Growth and characterization of LNCaP prostate cancer cell spheroids. Clin Cancer Res 1999;5:3171s-6s.
23. Kolbert KS, Sgouros G. Display and manipulation of SPECT and CT studies for radiolabeled antibody therapy [abstract]. Cancer Biother Radiopharm 1998;13:302.
24. Ballangrud AM, Yang WH, Charlton DE, et al. Response of LNCaP spheroids after treatment with an alpha-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591). Cancer Res 2001;61:2008-14.
25. Nikula TK, McDevitt MR, Finn RD, et al. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. J Nucl Med 1999;40:166-76.
26. Barendsen GW, Beusker TLJ, Vergroesen AJ, Budke L. Effect of different ionizing radiations on human cells in tissue culture. 2. Biological Experiments. Radiat Res 1960;13:841-9.
27. Sgouros G. Plasmapheresis in radioimmunotherapy of micrometastases: a mathematical modeling and dosimetrical analysis [see comments]. J Nucl Med 1992;33:2167-79.
28. DeNardo GL, Maddock SW, Sgouros G, Scheibe PO, DeNardo SJ. Immunoadsorption: an enhancement strategy for radioimmunotherapy. J Nucl Med 1993;34:1020-7.
29. Pimm MV, Andrew SM, Baldwin RW. Blood and fissue kinetics of radiolabelled anti-CEA monoclonal antibody and F(ab)2 and Fab fragments in nude mice with human tumour xenografts: implications for tumour imaging and radioimmunotherapy. Nucl Med Commun 1989;10:585-93.
30. Lewis GD, Figari I, Fendly B, et al. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 1993;37:255-63.
31. Shepard HM, Lewis GD, Sarup JC, et al. Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic J Clin Immunol 1991;11:117-27.
32. van Osdol W, Fujimori K, Weinstein JN. An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences of a "binding site barrier". Cancer Res 1991;51:4776-84.
33. Durand RE, Olive PL. Resistance of tumor cells to chemo- and radiotherapy modulated by the three-dimensional architecture of solid tumors and spheroids. Methods Cell Biol 2001;64:211-33.
34. Dean GS, Pusztai L, Xu FJ, et al. Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells. Clin Cancer Res 1998;4:2545-50.